PRODUCT TYPES – Page 32

Transport time excursion during transport to clinic: regulatory deviation handling

Detection of transport time excursions can originate from various signals experienced on the manufacturing floor or in quality control laboratories. The following symptoms often indicate potential deviations:Click to read the…

Biosimilar immunogenicity risk signal during stability pull comparisons: how to handle outliers and statistics without triggering inspection findings

Identifying symptoms of immunogenicity risk signals promptly is essential in ensuring that the quality and safety of biosimilars are not compromised. Symptoms may include:Click to read the full article.

Microbial limits failure during regulatory submission: regulatory communication strategy

Detecting a microbial limits failure begins with observing symptoms both on the production floor and within the laboratory environment. Key signals include:Click to read the full article.

Radiochemical purity OOS during inspection readiness: patient safety assessment

The identification of an OOS result for radiochemical purity may manifest in various ways on the production floor or laboratory. Key symptoms to monitor include:Click to read the full article.

Biosimilar comparability package deficiency after cell line or upstream change: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying symptoms is the first step in addressing a comparability package deficiency. Some common signals may include:Click to read the full article.

Labeling deviation during regulatory submission: regulatory communication strategy

The first indication of a labeling deviation typically emerges as either an internal observation or a complaint from regulatory bodies. Common symptoms observed on the production floor or in laboratories…

Transport time excursion during dispensing: patient safety assessment

Identifying deviations early can significantly mitigate risks associated with transport time excursions. Here are common signals that should prompt an immediate response:Click to read the full article.

Biosimilar method transfer failure across labs during CPV trending review: decision tree for lab method variability vs true product differences

Identifying the right symptoms is the first step in addressing biosimilar method transfer failures. Clinicians and laboratory technicians may observe discrepancies during stability testing, potency assays, or bioanalytical methods that…

Microbial limits failure during stability studies: GMP investigation and CAPA

The first step in addressing microbial limits failure during stability studies is the identification of symptoms or signals indicating a potential problem. Some key indicators that should alert staff to…

Half-life deviation during dispensing: patient safety assessment

Recognizing early symptoms of half-life deviations is critical in initiating an appropriate response. Symptoms can manifest in various forms, including:Click to read the full article.

Biosimilar regulatory deficiency during review during comparability protocol execution: bridging study planning and regulatory communication strategy

The first step in addressing a biosimilar regulatory deficiency is recognizing the signals that indicate a deviation may have occurred during the comparability protocol execution. Symptoms can manifest in several…

Stability failure during stability studies: regulatory communication strategy

Identifying symptoms or signals that suggest potential stability failures is critical in a timely intervention. Common indicators may include:Click to read the full article.